Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults A randomized open-label trial

被引:29
|
作者
Juergens, Christine [1 ]
de Villiers, Pierre J. T. [2 ]
Moodley, Keymanthri [2 ]
Jayawardene, Deepthi [3 ]
Jansen, Kathrin U. [3 ]
Scott, Daniel A. [3 ]
Emini, Emilio A. [3 ]
Gruber, William C. [3 ]
Schmoele-Thoma, Beate [1 ]
机构
[1] Pfizer GmbH, Berlin, Germany
[2] Univ Stellenbosch, ZA-7505 Tygerberg, South Africa
[3] Pfizer Inc, Pearl River, NY USA
关键词
13-valent pneumococcal conjugate vaccine; 23-valent pneumococcal polysaccharide vaccine; adults; elderly; immunogenicity; PCV13; PPSV23; safety; OPSONOPHAGOCYTIC ASSAY; RESPONSES;
D O I
10.4161/hv.27998
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This randomized open-label trial was designed to provide preliminary immunogenicity and safety data to support development of the pediatric 13-valent pneumococcal conjugate vaccine (PCV13) for adults. The aims were to: identify an age-appropriate PCV13 formulation, i.e., with (n = 309) or without (n = 304) aluminum phosphate (AlPO4); compare the selected PCV13 formulation (n = 309) with 23-valent pneumococcal polysaccharide vaccine (PPSV23; n = 301); and, together with an extension study, assess sequential use of pneumococcal vaccines at 1-year intervals in adults aged >= 65 years (n = 105) not pre-vaccinated with PPSV23. Immune responses were measured by ELISA and opsonophagocytic activity assays 1 month postvaccination. Immunoglobulin G responses elicited by PCV13 with AlPO4 and PCV13 without AlPO4 were similar for the majority, and noninferior for all PCV13 serotypes. PCV13 with AlPO4 was generally more reactogenic, with reactions mainly mild or moderate. Thus, PCV13 with AlPO4 (hereafter PCV13) became the selected formulation. Immune responses to PCV13 were noninferior for all but one serotype and for most PCV13 serotypes superior to PPSV23. Vaccine sequence assessments showed that for PCV13/PPSV23, the initial PCV13 dose generally enhanced responses to a subsequent PPSV23 dose, compared with PPSV23 alone. For PCV13/PCV13, a second dose did not enhance the first dose response when given after 1 year. For PCV13/PPSV23/PCV13, priming with PCV13 (vaccination 1) did not protect against lower responses induced by PPSV23 to subsequent PCV13 (vaccination 3). In conclusion, the pediatric PCV13 formulation with AlPO4 is well tolerated and immunogenic in adults, is generally more immunogenic than PPSV23, and subsequent vaccination with PPSV23 is possible if required.
引用
收藏
页码:1343 / 1353
页数:11
相关论文
共 50 条
  • [31] Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia
    Kattstrom, Magdalena
    Uggla, Bertil
    Tina, Elisabet
    Kimby, Eva
    Noren, Torbjorn
    Athlin, Simon
    VACCINE, 2023, 41 (19) : 3128 - 3136
  • [32] Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6-17 Years of Age in India An Open-label Trial
    Agarkhedkar, Sharad
    Juergens, Christine
    Balasundaram, Krishnamurthy
    Agarkhedkar, Shalaka
    Sundaraiyer, Vani
    Le Dren-Narayanin, Natacha
    Cutler, Mark W.
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2017, 36 (11) : E283 - E285
  • [33] Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
    Thompson, Allison R.
    Klein, Nicola P.
    Downey, H. Jackson
    Patterson, Scott
    Sundaraiyer, Vani
    Watson, Wendy
    Clarke, Keri
    Jansen, Kathrin U.
    Sebastian, Shite
    Gruber, William C.
    Scott, Daniel A.
    Schmoeele-Thoma, Beate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (02) : 444 - 451
  • [34] Immunogenicity and Safety of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan
    Togashi, Takehiro
    Yamaji, Masako
    Thompson, Allison
    Giardina, Peter C.
    Aizawa, Masakazu
    Patterson, Scott
    Gruber, William C.
    Scott, Daniel A.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (09) : 984 - 989
  • [35] Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia
    Urbancikova, Ingrid
    Prymula, Roman
    Goldblatt, David
    Roalfe, Lucy
    Prymulova, Karolina
    Kosina, Pavel
    VACCINE, 2017, 35 (38) : 5186 - 5193
  • [36] Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults
    Frenck, Robert W., Jr.
    Gurtman, Alejandra
    Rubino, John
    Smith, William
    van Cleeff, Martin
    Jayawardene, Deepthi
    Giardina, Peter C.
    Emini, Emilio A.
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    CLINICAL AND VACCINE IMMUNOLOGY, 2012, 19 (08) : 1296 - 1303
  • [37] Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
    Jackson, Lisa A.
    Gurtman, Alejandra
    van Cleeff, Martin
    Frenck, Robert W.
    Treanor, John
    Jansen, Kathrin U.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3594 - 3602
  • [38] Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects
    Ciprero, Karen
    Zykov, Kirill A.
    Briko, Nikolay I.
    Shekar, Tulin
    Sterling, Tina M.
    Bitieva, Elizaveta
    Stek, Jon E.
    Musey, Luwy
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (08) : 2142 - 2147
  • [39] Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan
    Hoshi, Shu-ling
    Kondo, Masahide
    Okubo, Ichiro
    PLOS ONE, 2015, 10 (10):
  • [40] Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Ngamprasertchai, Thundon
    Ruenroengbun, Narisa
    Kajeekul, Rattagan
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (02):